Genentech, Inc.

Symphony Evolution, Inc.

Array Biopharma Inc.

Genetech, Inc.

Zhaoyang Wen

Moon Jung Kim

Wei Xu

John M Nuss

Erick Wang Co

Donna Tra Le

Alexandre Joseph Buckmelter

Li Ren

David A Moreno

Steven Huy Do

Aleksandr Kolesnikov

Ellen Ruth Laird

Xiaojing Wang

Bainian Feng

Wendy Lee

Wendy B Young

Lynne Canne Bannen

Vasu Jammalamadaka

Brad Newhouse

Shumeye Mamo

Simon Mathieu

Janet Gunzner

Joachim Rudolph

Jonas Grina

Steven Mark Wenglowsky

Huiyong Hu

Kateri Ahrendt

Amy Lew

Kim Malesky

Joshua D Hansen

Jeongbeob Seo

Vickie Hsiao-Wei Tsui

Vickie H Tsui

Morrison B Mac

Richard George Khoury

Jason Jevious Parks

Amy Lew Tsuhako

Wei Cheng

Hongqi Tian

Rhett Ronald Klein

Jason De Meese

Paul Lunghofer

Moon Hwan Kim

Kateri A Ahrendt

Erick W Co

Pyrazolo[3,4-c]pyridine compounds of Formula I, including stereoisomers, geometric isomers, tautomers, and pharmaceutically acceptable salts thereof, wherein Rand Rare as defined herein, are useful for inhibiting Pim kinase, and for treating disorders such as cancer mediated by Pim kinase. Methods of using compounds of Formula I for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed. 

Pyrazolo[3,4-c]pyridine compounds and methods of use

Compounds of Formula I are useful for inhibition of Raf kinases. Methods of using compounds of Formula I and stereoisomers, tautomers, prodrugs and pharmaceutically acceptable salts thereof, for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions are disclosed. 

Pyrazole [3, 4-B] pyridine Raf inhibitors

Compounds of Formula (I) are useful for inhibition of Raf kinases. Methods of using compounds of Formula (I) and stereoisomers, tautomers, prodrugs and pharmaceutically acceptable salts thereof, for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions are disclosed. 

Raf inhibitor compounds and methods of use thereof

The present invention provides compounds useful for inhibiting the ADAM-10 protein, with selectivity versus MMP-1. Such compounds are useful in the in vitro study of the role of ADAM-10 (and its inhibition) in biological processes. The present invention also comprises pharmaceutical compositions comprising one or more ADAM-10 inhibitors according to the invention in combination with a pharmaceutically acceptable carrier. Such compositions are useful for the treatment of cancer, arthritis, and diseases related to angiogenesis. Correspondingly, the invention also comprises methods of treating forms of cancer, arthritis, and diseases related to angiogenesis in which ADAM-10 plays a critical role.

Human ADAM-10 inhibitors

The present invention provides compounds for modulating protein kinase enzymatic activity for modulating cellular activities such as proliferation, differentiation, programmed cell death, migration and chemoinvasion. More specifically, the invention provides oxindole derivatives which inhibit, regulate and/or modulate kinase receptor, particularly VEGF receptor 2 (Flk-1/KDR), FGFR1, and PDGFR (alpha and beta), signal transduction pathways related to the changes in cellular activities as mentioned above, compositions which contain these compounds, and methods of using them to treat kinase-dependent diseases and conditions.

Substituted 3-(diarylmethylene)indolin-2-ones and methods of their use

Growing community of inventors

San Francisco, CA, United States of America

Zhaoyang Wen